Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000488909
Ethics application status
Approved
Date submitted
9/05/2011
Date registered
10/05/2011
Date last updated
7/04/2014
Type of registration
Prospectively registered
Titles & IDs
Public title
The role of Vitamin C in managing type 2 diabetes: Vitamin C, Thiazolidinediones and their combined effect on
Adiponectin
Query!
Scientific title
People with Type 2 diabetes currently treated with thiazolidinediones supplemented with Vitamin C and the combined effect on adiponectin as a therapeutic for metabolic disease.
Query!
Secondary ID [1]
262126
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 diabetes
265799
0
Query!
Condition category
Condition code
Metabolic and Endocrine
265955
265955
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Dose escalation of Vitamin C supplementation, twice daily oral tablets, (500, 1000, 1500 and 2000 mg) for two weeks at each dose with no washout period in between. Vitamin C supplementation will be taken in addition to participants' existing thiazolidinedione treatment which will continue as usual.
Query!
Intervention code [1]
264541
0
Treatment: Other
Query!
Comparator / control treatment
None
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
266705
0
Increase in high molecular weight adiponectin assessed using a blood test and subsequent laboratory analysis of the sample.
Query!
Assessment method [1]
266705
0
Query!
Timepoint [1]
266705
0
At the start of the trial, fortnightly after each increase in Vitamin C dosage and then a fortnight after the final Vitamin C dosage is complete.
Query!
Secondary outcome [1]
276243
0
Nil
Query!
Assessment method [1]
276243
0
Query!
Timepoint [1]
276243
0
Nil
Query!
Eligibility
Key inclusion criteria
Female or male participants between the ages of 18 and 70 with non insulin dependent type 2 diabetes under TZD treatment (either rosiglitazone 4 – 8 mg or piogitazone greater than or equal 30 mg) with or without metformin.
HbA1C level 7 – 8.5 %.
Participant on stable diabetic therapy for three months prior to the intervention.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
HbA1C level greater than 8.5 %
Participants must have a stable body weight (< 5% selfreported weight loss/gain) within last 3 months prior to enrolment.
Participants taking iron supplements.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
10/05/2011
Query!
Actual
18/11/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
265024
0
Government body
Query!
Name [1]
265024
0
Queensland Department of Employment, Economic Development and Innovation
Query!
Address [1]
265024
0
Queensland Government
PO Box 15168, City East, Qld, 4002
Query!
Country [1]
265024
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Princess Alexandra Hospital
Query!
Address
199 Ipswich Road Woolloongabba, Brisbane, Queensland, 4102
Query!
Country
Australia
Query!
Secondary sponsor category [1]
264120
0
University
Query!
Name [1]
264120
0
University of Queensland
Query!
Address [1]
264120
0
The University of Queensland
Brisbane QLD 4072 Australia
Query!
Country [1]
264120
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
267006
0
Metro South Health Service District Human Research Ethics Committee (EC00167)
Query!
Ethics committee address [1]
267006
0
Centres for Health Research Level 2, Building 35
Princess Alexandra Hospital
Ispwich Road WOOLLOONGABBA QLD 4102
Query!
Ethics committee country [1]
267006
0
Australia
Query!
Date submitted for ethics approval [1]
267006
0
Query!
Approval date [1]
267006
0
21/04/2011
Query!
Ethics approval number [1]
267006
0
EC00167
Query!
Summary
Brief summary
Thiazolidinediones (TZD) are a class of drug commonly prescribed to manage type 2 diabetes. While the exact
mechanism of action is unknown, efficacy of the drug is closely correlated with improved circulating concentration of
a protein, adiponectin, secreted by fat tissue. Adiponectin is decreased in many diseases states including type 2
diabetes. Adiponectin is secreted as multimers of different sizes, termed low molecular weight (LMW) and high
molecular weight (HMW), and while an increase in circulating adiponectin is beneficial, it is more specifically an
increase in the HMW multimers that is correlated with improvement in health. An improvement in adiponectin profile refers to an increase in the proportion of the multimers present as HMW and may also be concomitant with an increase in total adiponectin.
Previous studies have demonstrated that high dose Vitamin C alone can improve glucose control in obese and
diabetic patients. Researchers involved with the proposed research project have demonstrated that combining
Vitamin C with TZD treatment has a synergistic effect on adiponectin profile in vitro in a human adipose cell line.
Vitamin C alone improves adiponectin profile 1.7 fold, while improvements are 5 fold over baseline when in
combination with TZD. Combining the evidence from previous studies and these in vitro observations
demonstrates a potential for combining TZD with high dose Vitamin C to get an improved treatment for managing
type 2 diabetes.
Research Design and Methods: Patients will have a two week wash out period to control vitamin c levels, and then
two weekly intervals on escalating doses of oral vitamin C for 8 weeks (4 doses, 500 mg / day, 1000 mg / day, 1500
mg / day and 2000 mg / day). Each patient will serve as their own control, with assessment of total and HMW
adiponectin at the beginning and end of the trial and at dose escalation points in between as primary endpoints.
Other indicators of improvement in metabolic parameters will also be monitored.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32578
0
A/Prof Anthony Russell
Query!
Address
32578
0
Department of Diabetes and Endocrinology, Ground Floor Building 1, Princess Alexandra Hospital 199 Ipswich Road Woolloongabba QLD 4102
Query!
Country
32578
0
Australia
Query!
Phone
32578
0
+61 7 3240 5914
Query!
Fax
32578
0
Query!
Email
32578
0
[email protected]
Query!
Contact person for public queries
Name
15825
0
A/Prof Associate Professor Anthony Russell
Query!
Address
15825
0
Department of Diabetes and Endocrinology, Ground Floor
Building 1, Princess Alexandra Hospital
199 Ipswich Road
Woolloongabba QLD 4102
Query!
Country
15825
0
Australia
Query!
Phone
15825
0
+61 7 3240 5914
Query!
Fax
15825
0
Query!
Email
15825
0
[email protected]
Query!
Contact person for scientific queries
Name
6753
0
A/Prof Associate Professor Anthony Russell
Query!
Address
6753
0
Department of Diabetes and Endocrinology, Ground Floor
Building 1, Princess Alexandra Hospital
199 Ipswich Road
Woolloongabba QLD 4102
Query!
Country
6753
0
Australia
Query!
Phone
6753
0
+61 7 3240 5914
Query!
Fax
6753
0
Query!
Email
6753
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF